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Summary The guidelines of the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) do not recommend the measurement of pulmonary artery pressure in patients
with chronic obstructive pulmonary disease (COPD). This is on the basis that the mean
pulmonary artery pressure (mPAP) does not provide more clinical information than
measurement of the oxygen tension in arterial blood (PaO2). The mPAP correlates well
with PaO2 in emphysema patients with severe hypoxemia (PaO2p7.3 kPa (55mmHg)).
However, the occurrence and significance of mPAP is unclear in patients without
severe hypoxemia (PaO247.3 kPa (55mmHg)). In order to evaluate the usefulness of
measurement of mPAP in emphysema patients without severe hypoxemia, we
performed right heart catheterization and investigated the pulmonary hemodynamics
of 53 patients without severe hypoxemia. In addition, we identified long-term
prognostic factors with a mean follow-up term of 77 months after right heart
catheterization. Seventeen of 27 patients with mild-to-moderate hypoxemia
exhibited pulmonary hypertension (mPAPX2.7 kPa (20mmHg)) and the classification
according to severity in GOLD exhibited a greater correlation to mPAP than PaO2.
Moreover, only mPAP was found to be a significant prognostic factor according to
multivariate proportional hazards analysis (P ¼ 0:01). We conclude that mPAP is more
informative about the severity of emphysema than PaO2 in patients with mild-to-
moderate hypoxemia.
r 2003 Elsevier Ltd. All rights reserved.
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Introduction
The prognostic factors in chronic obstructive
pulmonary disease (COPD) patients with severe
hypoxemia (PaO2p7.3 kPa (55mmHg)) have been
well analyzed. Forced expiratory volume in 1 s
(FEV1.0), arterial blood gas values (PaO2 and PaCO2;
carbon dioxide tension in arterial blood), age,
nutritional status, dyspnea and mean pulmonary
artery pressure (mPAP) have been demonstrated to
be good indicators of patient prognosis.1–5 Several
studies have indicated that long-term oxygen
therapy (LTOT) stabilizes and may even reverse
the progression of pulmonary hypertension,6–9 and
has been shown to result in improved survival in
hypoxemic COPD patients. According to these
observations, the current indications for this
therapy are the severity of the hypoxemia
(PaO2p7.3 kPa) or pulmonary hypertension and
right heart failure at a PaO2 of 7.3–8.0 kPa.
On the other hand, the occurrence of pulmonary
hypertension remains unclear in patients without
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severe hypoxemia (PaO247.3 kPa). Global guide-
lines for COPD were jointly published by the
National Heart, Lung, and Blood Institute (NHLBI)/
World Health Organization (WHO) in 2001 (Global
Initiative for Chronic Obstructive Lung Disease,
GOLD guidelines) for the purpose of educating
about COPD and setting global standards for the
diagnosis, management and prevention of COPD.
The measurement of mPAP is not considered to be
necessary according to these guidelines on the
grounds that it does not provide more clinical
information than PaO2.
In the present study, we investigated pulmonary
hemodynamic parameters using cardiac catheter-
ization in emphysema patients without severe
hypoxemia (PaO247.3 kPa) and evaluated the sig-
nificance of mPAP measurement.
Materials and methods
Fifty-three patients with a diagnosis of pulmonary
emphysema without severe hypoxemia (PaO24
7.3 kPa) were obtained from those patients treated
at Kure National Hospital from 1985 to 1993. This
study was performed as the work of a research and
investigation team for respiratory failure in the
Ministry of Health and Welfare of Japan, and was
approved by the clinical research committee of the
Institute. Written informed consent was obtained
from all patients. Patients underwent right heart
catheterization and were followed up to August
1999. In this study, emphysema was defined on both
clinical and functional criteria. We selected pa-
tients with emphysema prior to the initiation of
LTOT who were dyspneic on exertion and whose
FEV1.0/vital capacity ratio (FEV1.0%) was less than
70% when they were free of acute exacerbation.
We examined the complete clinical history, physical
examination findings and the results of basic
laboratory tests of the patients. mPAP and mixed
venous oxygen tension were measured by Swan–
Ganz balloon-tipped catheters in the supine posi-
tion without premedication. Cardiac output was
calculated according to Fick’s principle. Pulmonary
and static volumes were measured twice by
conventional spirometry with an interval of 4 weeks
and arterial blood gas levels were measured while
breathing room air after a 15min resting period in
the supine position. Patients with sleep apnea
syndrome, left heart disease and/or other severe
diseases such as malignant tumors, hepatic cirrho-
sis and chronic renal failure that could influence
their survival were excluded from the study.
Bronchodilators such as theophylline, b2 agonists
and anticholinergic drugs were prescribed to most
patients during the study period. Antibiotics,
diuretics, and corticosteroids were prescribed at
the discretion of physicians.
We divided the patients according to the degree
of obstruction into four groups according to GOLD:
Stage I: percent of FEV1.0 predicted (FEV1.0%
pred)X80%; Stage IIA: 50%pFEV1.0%predo80%;
Stage IIB: 30%pFEV1.0%predo50%; Stage III:
FEV1.0%predo30%.
Statistical analysis
Data are expressed as mean and standard devia-
tion. Differences of measured variables between
groups were assessed using analysis of variance and
Kruskal–Wallis test. P values less than 0.05 were
considered to be statistically significant. Survival
was calculated from the day when the cardiac
catheterization was performed to the day the
patient died or to the end of the study. The
multivariate analysis of factors affecting survival
was performed by Cox’s model of proportional
hazards regression. Survival curves were drawn
using the Kaplan–Meier method and the log-rank
statistic was used to confirm the lack of difference
in survival between two groups.
Results
Patients
The study group included 49 men and four women
(mean age 7177.6 years) (Table 1). The average of
follow-up period was 76.7 months (range: 2–161
months). The degree of dyspnea was 2.771.0
according to the American Thoracic Society (ATS)
scale. The serum albumin and blood hemoglobin
were 609772 mmol/l (4.270.5 g/dl) and 9.07
0.9mmol/l (14.571.5 g/dl), respectively, while
the body mass index was 18.972.9 kg/m2. The
FEV1.0%pred, percent of vital capacity (%VC),
PaO2 and PaCO2 were 39.8716.2%, 73.0719.3%,
9.571.2 kPa (70.979.0mmHg) and 5.670.8 kPa
(41.975.7mmHg), respectively. The mPAP was
2.570.6 kPa (19.074.3mmHg) (Table 2).
Relationship between the degree of
hypoxemia and pulmonary artery pressure
We divided the patients according to the PaO2
values into three groups (Table 1): mode-
rate hypoxemia, 7.3oPaO2p8.7 kPa (55oPaO2p
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65mmHg); mild hypoxemia, 8.7oPaO2p9.3 kPa
(65oPaO2p70mmHg); and normal, PaO249.3 kPa
(70mmHg). The mPAP of these patient groups
were 2.870.5 kPa (21.274.1mmHg), 2.770.6 kPa
(20.574.4mmHg) and 2.370.5 kPa (17.17
3.5mmHg), respectively. The patients with mild-
to-moderate hypoxemia (7.3oPaO2p9.3 kPa) ex-
hibited a significantly higher pulmonary artery
pressure than those with a normal PaO2 (PaO24
9.3 kPa, P ¼ 0:0009). Seventeen of 27 (63%)
patients with mild-to-moderate hypoxemia exhib-
ited pulmonary hypertension (mPAP42.7 kPa
(20mmHg)).
Relationship between the classification by
severity in gold and hypoxemia and mPAP
Fig. 1 depicts the prevalence of PaO2 and mPAP
according to the staging system for COPD described
in GOLD. The prevalence of PaO2 showed no
significant difference between stages according to
FEV1.0%pred (Fig. 1A). However, mPAP increased
significantly according to increased severity of
airflow limitation (Fig. 1B). There was a good
correlation between mPAP and FEV1.0%pred (R ¼
0:494; P ¼ 0:0002) while PaO2 also exhibited a
significant correlation with FEV1.0%pred (R ¼
0:303; P ¼ 0:03).
Analysis of prognostic factors
Seventeen of the 53 patients were alive at the end
of the study while 36 patients had died, with the
deaths of 21 being directly related to worsening of
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Table 1 Patient characteristics (n ¼ 53)
Gender
Male 49
Female 4
Age (years)
50–59 5
60–69 15
70–79 29
80–89 4
Dyspnea
(ATS scale*)
0 0
I 3
II 21
III 10
IV 14
Unknown 5
PaO2**
(kPa)
7.3–8.7 15
8.7–9.3 12
49.3 26
*ATS scale: American Thoracic Society scale.
**PaO2: oxygen tension in arterial blood.
Table 2 Pulmonary hemodynamic data (n ¼ 53)
Mean pulmonary artery
pressure (kPa)
2.570.6
Pulmonary vascular
resistance (kPa/l)
21.778.4
Mixed venous blood oxygen
tension (kPa)
5.170.7
Cardiac index (l/minm2) 3.070.7
Pulmonary capillary wedge
pressure (kPa)
1.070.4
Data are expressed as the mean7SD.
Figure 1 We divided the patients according to the
degree of obstruction into four groups according to
GOLD: Stage I: FEV1.0%predX80%, n ¼ 2; Stage IIA: 50%p
FEV1.0%predo80%, n ¼ 8; Stage IIB: 30%pFEV1.0%pre-
do50%, n ¼ 28; Stage III: FEV1.0%predo30%, n ¼ 14: The
PaO2 of these groups were 9.371.5 kPa (69.6711.2 Torr),
10.571.7 kPa (78.8712.7 Torr), 9.170.9 kPa (68.67
6.8 Torr) and 9.370.9 kPa (69.576.7 Torr), respectively
(Fig. 1A). The mPAP was 1.970.2 kPa (14.071.4 Torr),
2.170.5 kPa (15.673.7 Torr), 2.670.5 kPa (19.77
3.4 Torr) and 2.870.7 kPa (20.774.9 Torr) respectively
(Fig. 1B). mPAP was well correlated with the stages
defined by GOLD (Po0:0001) (Fig. 1B).
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their emphysema. The other 15 patients died of
various conditions including malignant tumors,
pneumonia and ileus. The prognostic factors in 38
patients, i.e. excluding the patients who died of
diseases other than respiratory failure, are shown
in Table 3. The log-rank test indicated that mPAP,
dyspnea (ATS scale), age and PVR were significant
prognostic factors. However, only mPAP was
demonstrated to be significant (P ¼ 0:01) follow-
ing subsequent multivariate proportional hazards
analysis.
We then divided the 53 patients according to the
mPAP values into two groups. The survival curves of
the groups with and without pulmonary hyperten-
sion (mPAPX2.7 kPa and mPAPo2.7 kPa) are shown
in Fig. 2. The group with pulmonary hypertension
included 23 patients and the group without
pulmonary hypertension consisted of 30 patients.
Statistical analysis indicated that the patients with
pulmonary hypertension had a significantly worse
prognosis (P ¼ 0:0001).
Discussion
In our study, all patients did not exhibit severe
hypoxemia. However, according to the staging
system in GOLD, 64% of our patients were classified
as Stage IIB and 26% were classified as Stage III.
PaO2 values did not exhibit a significant difference
between the stages according to GOLD, whereas
mPAP demonstrated a significant increase accord-
ing to increased severity of airflow limitation and
correlated with the stages defined by GOLD. This
result indicates that mPAP is a more useful
indicator of the severity of emphysema than PaO2
in patients without hypoxemia. MPAP in Stage III
was 2.870.7 kPa (20.774.9mmHg) and pulmonary
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Figure 2 Cumulative survival rate for patients with
pulmonary hypertension (mPAPX2.7 kPa) and those with-
out pulmonary hypertension (mPAPo2.7 kPa). The group
with pulmonary hypertension consisted of 23 patients and
the group without pulmonary hypertension consisted of
30 patients. The patients with pulmonary hypertension
exhibited a significantly worse prognosis (P ¼ 0:0001).
Table 3 Univariate and multivariate analysis of prognostic factors of survivors and those who died due to
respiratory failure (n ¼ 38)
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P Adjusted hazard ratio (95% CI) P
mPAP (o2.7 kPa) 5.80 (2.11–16.0) 0.0007 4.38 (1.34–14.3) 0.01
ATS scale (I, II, III/IV) 0.18 (0.07–0.48) 0.0005 0.29 (0.09–0.97) 0.05
Age (o70 years) 3.52 (1.28–9.70) 0.02 2.86 (0.77–10.6) 0.12
PVR (o200 kPa/l) 2.80 (1.10–7.12) 0.03 1.70 (0.50–5.81) 0.40
PvO2 (o4.7 kPa) 0.37 (0.13–1.02) 0.05
BMI (o20 kg/m2) 0.59 (0.22–1.61) 0.30
Brinkmann index (o500) 0.50 (0.14–1.79) 0.29
Hb (o8.69mmol/l) 0.84 (0.32–2.26) 0.73
Alb (o580 mmol/l) 0.54 (0.20–1.43) 0.21
FEV1.0%pred (o35% ) 0.61 (0.25–1.52) 0.29
%VC (o70%) 0.44 (0.18–1.06) 0.07
PaO2 (o9.3 kPa) 0.89 (0.38–2.10) 0.79
PaCO2 (o6.0 kPa) 1.32 (0.55–3.19) 0.54
CI (o3.0 l/minm2) 0.51 (0.19–1.36) 0.18
mPAP¼mean pulmonary artery pressure, ATS¼American Thoracic Society, PVR¼pulmonary vascular resistance, PvO2¼mixed
venous blood oxygen tension, BMI¼body mass index, Hb¼ hemoglobin, Alb¼ albumin, FEV1.0%pred¼percent of forced
expiratory volume in 1 s predicted, %VC¼percent of vital capacity, PaO2¼ oxygen tension in arterial blood, PaCO2¼ carbon
dioxide tension in arterial blood, CI¼ cardiac index.
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vascular resistance as a whole average was
21.7 kPa/l (normal range: 4.5–10 kPa/l), on the
other hand, cardiac index was within normal range
and erythrocytosis was not recognized. All of our
patients did not exhibit any symptoms of right
heart failure at the cardiac catheterization, there-
fore the prevalence of pulmonary hypertension
could not have been predicted. Scharf et al.10
evaluated 120 emphysema patients without severe
hypoxemia, and showed that DLCO%, PCWP and
FEV1.0%pred but not PaO2 were significant predic-
tors of mPAP by multiple regression analysis. In
comparison with our patients, the patients studied
by Scharf et al. had considerably more severe
disease, e.g. the mean values of their FEV1.0%pred
and mPAP were 27% and 3.5 kPa (26.3mmHg),
respectively. This result is in accordance with our
data in that the pulmonary artery pressure in-
creased according to increased severity of airflow
limitation, and supports our consideration that
mPAP is more sensitive and may reflect the severity
of disease better than PaO2 in emphysema patients
without severe hypoxemia.
The prognostic value of the presence of pulmon-
ary hypertension in COPD patients with severe
hypoxemia is in accordance with the results
obtained by previous investigators.1–5 On the other
hand, in patients with mild-to-moderate hypoxe-
mia the prognostic value of pulmonary hyperten-
sion has been unclear. In our study, mPAP, dyspnea
(ATS scale), age and PVR were found to be
significant prognostic factors in univariate analysis.
However, in subsequent multivariate analysis, only
mPAP was found to be significant. The studies of
Gorecka et al.11 and Anthonisen et al.12 indicated
that younger age, better spirometric values and
higher body mass index were predictors of im-
proved survival in COPD patients with mild-to-
moderate hypoxemia. In our study, univariate
analysis of long-term prognostic factors indicated
that, similar to their results, age was a prognostic
factor but spirometric values were not prognostic
factors. Anthonisen et al.12 indicated that patients
with low initial values of FEV1.0 showed relatively
little decline of FEV1.0% during the observation
period. Our subjects showed lower initial values of
FEV1.0%pred than the patients in their study, and
this may explain why FEV1.0%pred was not a
significant prognostic factor in our study.
On the other hand, univariate analysis indicated
that patients with severe dyspnea (ATS scale IV)
exhibited a worse prognosis than patients with
mild-to-moderate dyspnea (ATS scale I, II, III). A
strong correlation was recognized between dyspnea
and mPA (jRj ¼ 0:67) and FEV1.0%pred (jRj ¼ 0:61),
although the correlation coefficient with PaO2 was
0.15. This result suggests that patients exhibiting
severe dyspnea even with light exercise have
severe airway limitation and pulmonary hyperten-
sion even in the absence of severe hypoxemia at
rest.
Multivariate analysis showed that only mPAP was
an independent prognostic factor. However, the
progression of mPAP in COPD patients has been
observed to be very slow, as the average increase of
mPAP was 0.4–0.5mmHg/yr.13,14 Kessler et al.14
assessed the evolution of pulmonary hemodynamics
in 131 COPD patients with mild-to-moderate
hypoxemia without pulmonary hypertension by
performing two right heart catheterizations at a
mean time interval of 6.8 year. In their study, the
resting and exercising mPAP at the onset were
independent predictors for the subsequent devel-
opment of pulmonary hypertension. Moreover, in
patients with an accelerated worsening of resting
mPAP a significant worsening of exercising mPAP
was recognized between two intervals, whereas
the changes of FEV1.0 and PaO2 were not significant.
Our study does not have complete data regarding
pulmonary hemodynamics during exercise; how-
ever, the findings of Kessler et al.14 suggest the
possibility that our patients with high mPAP showed
marked elevation of mPAP on exercise and/or
significant worsening of exercising mPAP in pro-
gress.
Right heart catheterization is the most accurate
method for the evaluation of pulmonary hemody-
namics but it is not performed routinely because it
is invasive and expensive. Instead, various non-
invasive approaches have been used including
imaging techniques such as nuclear medicine,
real-time sonography, color Doppler echography,
CT and MRI.15,16 Recently, Matsuyama et al.17
demonstrated that the transcutaneous measure-
ment of jugular venous flow velocity by Doppler
jugular venous echo might have a potential role in
the prediction of pulmonary hypertension. In
emphysema patients, lung hyperinflation has made
the assessment of right ventricular volumes proble-
matic and this transcutaneous Doppler jugular
venous echo may therefore be a useful tool to
monitor pulmonary artery pressure.
In summary, the prevalence of pulmonary hyper-
tension was high in emphysema patients with mild-
to-moderate hypoxemia, and only mPAP was a
significant prognostic factor by multivariate analy-
sis. Although our study has some limitations
because of the small number of subjects, mPAP
exhibited a greater correlation than PaO2 with the
staging system of severity in GOLD in patients
without severe hypoxemia. However, the values of
mPAP were various in patients of each stage as
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shown in Fig. 1., therefore we need to evaluate the
patients with high mPAP appropriately and follow-
up and prevent its progression.
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